Literature DB >> 28812223

Prognostic potential of KLOTHO and SFRP1 promoter methylation in head and neck squamous cell carcinoma.

Abeer A Alsofyani1, Rawiah A Alsiary1, Alaa Samkari1, Baraa T Alhaj-Hussain2, Jalaluddin Azam Khan3, Jaudah Al-Maghrabi4, Aisha Elaimi5, Mohammed H Al-Qahtani5, Adel M Abuzenadah5, Ashraf Dallol6.   

Abstract

Hypermethylation in the CpG island promoter regions of tumor suppressors is known to play a significant role in the development of HNSCC and the detection of which can aid the classification and prognosis of HNSCC. This study aims to profile the methylation patterns in a panel of key genes including CDKN2A, CDKN2B, KLOTHO (KL), RASSF1A, RARB, SLIT2, and SFRP1, in a group of HNSCC samples from Saudi Arabia. The extent of methylation in these genes is determined using the MethyLight assay and correlated with known clinicopathological parameters in our samples of 156 formalin-fixed and paraffin-embedded HNSCC tissues. SLIT2 methylation had the highest frequency (64.6%), followed by RASSF1A (41.3%), RARB (40.7%), SFRP1 (34.9), KL (30.7%), CKDN2B (29.6%), and CKDN2A (29.1%). KL and SFRP1 methylation were more predominant in nasopharyngeal tumors (P = 0.001 and P = 0.031 respectively). Kaplan Meier analysis showed that patients with moderately differentiated tumors who display SFRP1 methylation have significantly worse overall survival in comparison with other samples. In contrast, better clinical outcomes were seen in patients with KL methylation. In conclusion, our findings suggest that the detection of frequent methylation in SFRP1 and KL genes' promoters could serve as prognostic biomarkers for HNSCC.

Entities:  

Keywords:  Head and neck squamous cell carcinoma; KLOTHO methylation; Prognostic biomarkers; Promoter region hypermethylation; SFRP1 methylation

Mesh:

Substances:

Year:  2017        PMID: 28812223     DOI: 10.1007/s13353-017-0404-7

Source DB:  PubMed          Journal:  J Appl Genet        ISSN: 1234-1983            Impact factor:   3.240


  39 in total

Review 1.  The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.

Authors:  Panagiota Economopoulou; Christos Perisanidis; Evaggelos I Giotakis; Amanda Psyrri
Journal:  Ann Transl Med       Date:  2016-05

2.  Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer.

Authors:  Carmen J Marsit; Margaret R Karagas; Angeline Andrew; Mei Liu; Hadi Danaee; Alan R Schned; Heather H Nelson; Karl T Kelsey
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

3.  Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.

Authors:  Tamotsu Kuroki; Francesco Trapasso; Sai Yendamuri; Ayumi Matsuyama; Hansjuerg Alder; Masaki Mori; Carlo M Croce
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

4.  Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma.

Authors:  Ali Fendri; Asma Masmoudi; Abdelmajid Khabir; Tahia Sellami-Boudawara; Jamel Daoud; Mounir Frikha; Abdelmonem Ghorbel; Ali Gargouri; Raja Mokdad-Gargouri
Journal:  Cancer Biol Ther       Date:  2009-03-21       Impact factor: 4.742

5.  Promoter hypermethylation of mismatch repair genes, hMLH1 and hMSH2 in oral squamous cell carcinoma.

Authors:  R Czerninski; S Krichevsky; Y Ashhab; D Gazit; V Patel; D Ben-Yehuda
Journal:  Oral Dis       Date:  2009-01-16       Impact factor: 3.511

6.  Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma.

Authors:  Biao Xie; Jianping Zhou; Lianwen Yuan; Feng Ren; Dong-cai Liu; Qinglong Li; Guoshun Shu
Journal:  Hum Pathol       Date:  2012-10-31       Impact factor: 3.466

Review 7.  Molecular biology of head and neck cancer: risks and pathways.

Authors:  Michael E Stadler; Mihir R Patel; Marion E Couch; David Neil Hayes
Journal:  Hematol Oncol Clin North Am       Date:  2008-12       Impact factor: 3.722

8.  Role of DNA methylation in head and neck cancer.

Authors:  Semra Demokan; Nejat Dalay
Journal:  Clin Epigenetics       Date:  2011-07-09       Impact factor: 6.551

Review 9.  Aberrant Methylation of RASSF1A Closely Associated with HNSCC, a Meta-Analysis.

Authors:  Rui-Wei Meng; Yun-Cheng Li; Xiong Chen; Yang-Xin Huang; Hao Shi; Dan-Dan Du; Xun Niu; Cheng Lu; Mei-Xia Lu
Journal:  Sci Rep       Date:  2016-02-09       Impact factor: 4.379

10.  Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival.

Authors:  Aleksandra Majchrzak-Celińska; Marta Słocińska; Anna-Maria Barciszewska; Stanisław Nowak; Wanda Baer-Dubowska
Journal:  J Appl Genet       Date:  2015-09-04       Impact factor: 3.240

View more
  3 in total

1.  hTERT promoter methylation status in peripheral blood leukocytes as a molecular marker of head and neck cancer progression.

Authors:  Agnieszka Sobecka; Wiktoria Blaszczak; Wojciech Barczak; Pawel Golusinski; Blazej Rubis; Michal M Masternak; Wiktoria M Suchorska; Wojciech Golusinski
Journal:  J Appl Genet       Date:  2018-08-07       Impact factor: 3.240

2.  DNA methylation-mediated Klotho silencing is an independent prognostic biomarker of head and neck squamous carcinoma.

Authors:  Yun Zhu; Xuehong Cao; Xiaomeng Zhang; Quan Chen; Lei Wen; Ping Wang
Journal:  Cancer Manag Res       Date:  2019-02-12       Impact factor: 3.989

3.  Prognostic Relevance of SFRP1 Gene Promoter Methylation in Colorectal Carcinoma

Authors:  Alok Kumar; Sunil Babu Gosipatala; Anshuman Pandey; Pradyumn Singh
Journal:  Asian Pac J Cancer Prev       Date:  2019-05-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.